Tg Therapeutics (TGTX) EBITDA (2011 - 2026)

Tg Therapeutics' EBITDA history runs 16 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• In Q1 2026, EBITDA rose 303.56% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at $149.5 million (up 149.91% YoY), while the FY2025 annual figure was $123.3 million, up 194.13% from the prior year.
• EBITDA was $34.8 million for Q1 2026 at Tg Therapeutics, down from $50.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $114.8 million in Q3 2023 to a low of -$77.5 million in Q4 2022.
• Historically, EBITDA has averaged -$913176.5 across 5 years, with a median of $8.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 428.3% in 2023, then tumbled 89.17% in 2024.
• A 5-year view of EBITDA shows it stood at -$77.5 million in 2022, then jumped by 60.83% to -$30.4 million in 2023, then soared by 198.6% to $29.9 million in 2024, then soared by 68.6% to $50.5 million in 2025, then plunged by 31.09% to $34.8 million in 2026.
• The last three EBITDA figures came in at $34.8 million (Q1 2026), $50.5 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.